A detailed history of Alpha Dna Investment Management LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Alpha Dna Investment Management LLC holds 9,414 shares of HALO stock, worth $453,095. This represents 0.21% of its overall portfolio holdings.

Number of Shares
9,414
Previous 8,476 11.07%
Holding current value
$453,095
Previous $443,000 21.44%
% of portfolio
0.21%
Previous 0.18%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$51.3 - $64.42 $48,119 - $60,425
938 Added 11.07%
9,414 $538,000
Q2 2024

Aug 14, 2024

BUY
$37.81 - $52.4 $68,058 - $94,320
1,800 Added 26.96%
8,476 $443,000
Q1 2024

May 15, 2024

BUY
$33.68 - $41.95 $224,847 - $280,058
6,676 New
6,676 $271,000
Q2 2021

Aug 10, 2021

SELL
$38.84 - $51.31 $4,233 - $5,592
-109 Closed
0 $0
Q1 2021

May 12, 2021

BUY
$39.51 - $51.45 $4,306 - $5,608
109 New
109 $4,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.7B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Alpha Dna Investment Management LLC Portfolio

Follow Alpha Dna Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Dna Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Dna Investment Management LLC with notifications on news.